Abstracts tagged "Adalimumab"

Abstract Number: 2639 • 2016 ACR/ARHP Annual Meeting
Predicting Flare and Sustained Clinical Remission after Adalimumab Withdrawal Using the Multi-Biomarker Disease Activity (MBDA) Score
Shintaro Hirata¹, Xingbin Wang², CC Hwang³, Ippei Miyagawa⁴, Satoshi Kubo¹, Kazuhisa Nakano⁵, Shingo Nakayamada⁵, Kazuyoshi Saito⁴, Nadine A. Defranoux² and Yoshiya Tanaka⁶, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²Crescendo Bioscience Inc., South San Francisco, CA, ³Biostatistics, Crescendo Bioscience Inc., South San Francisco, CA, ⁴University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁵First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁶University of Occupational and Environmental Health, Kitakyushu, Japan
Background/Purpose: The multi-biomarker disease activity (MBDA) (Vectra® DA) score has been reported to predict disease relapses in patients with rheumatoid arthritis (RA) in sustained remission…
Abstract Number: 392 • 2016 ACR/ARHP Annual Meeting
Safety and Clinical Response of Weekly Adalimumab in the Treatment of Juvenile Idiopathic Arthritis, Pediatric Chronic Uveitis and Other Childhood Rheumatic Diseases
Colleen K. Correll¹, Danielle R. Bullock¹, Rachel Cafferty¹ and Richard K Vehe², ¹Pediatrics, University of Minnesota, Minneapolis, MN, ²University of Minnesota Masonic Children’s Hospital, Minneapolis, MN
Background/Purpose: Every other week adalimumab is used to treat juvenile idiopathic arthritis (JIA) and other pediatric rheumatic diseases. It is common for pediatric rheumatologists to…
Abstract Number: 1245 • 2016 ACR/ARHP Annual Meeting
Comparison of Secukinumab Vs Adalimumab in a Cost per Responder Analysis Based on a Matching-Adjusted Indirect Comparison of Efficacy Data for the Treatment of Psoriatic Arthritis at 48 Weeks from the US Perspective
Jeffrey D. Greenberg¹, Efthalia Nikoglou², Praveen Gunda³, Jacqueline Palmer⁴ and Steffen Jugl⁵, ¹Corrona, LLC, Southborough, MA, ²Novartis Ireland, Ltd, Dublin, Ireland, ³Novartis Healthcare Pvt. Ltd., Hyderabad, India, ⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁵Novartis Pharma AG, Basel, Switzerland
Comparison of Secukinumab vs Adalimumab in a cost per responder analysis based on a matching-adjusted indirect comparison of efficacy data for the treatment of psoriatic…
Abstract Number: 2941 • 2016 ACR/ARHP Annual Meeting
Optimization of Adalimumab on Refractory Uveitis of Behcet’s Syndrome. Multicenter Study of 23 Patients
Carlos Fernández-Díaz¹, Ricardo Blanco¹, Vanesa Calvo-Río¹, Javier Loricera¹, J. Sanchez-bursón², Norberto Ortego Centeno³, Jose L. García Serrano⁴, Miguel Cordero⁵, J. Vazquez⁶, Emma Beltran⁷, Elia Valls⁸, O. Maiz Alonso⁹, Ana Blanco¹⁰, Ignacio Torre¹¹, Angel García-Aparicio¹², F.j Toyos-saénz¹³, L. Martinez-Costa¹⁴, Lucia C. Domínguez-Casas¹, Natalia Palmou¹ and Miguel Angel Gonzalez-Gay¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ²Rheumatology, Hospital Valme, Hospital Valme, Sevilla, Spain, ³Medicine Department, Hospital Universitario San Cecilio, Granada, Spain, ⁴Ophthalmology, Hospital Universitario San Cecilio, Granada, Spain, ⁵Ophthalmology, Hospital de León, León, Spain, ⁶Rheumatology, Hospital de Ferrol, Ferrol, Spain, ⁷Rheumatology, Hospital General Universitario de Valencia, Valencia, Spain, ⁸Rheumatology, Hospital Dr. Peset., Valencia, Spain, ⁹Rheumatology, Hospital Donostia, San Sebastian, Spain, ¹⁰Ophthalmology Department. Donostia University Hospital, Donostia, Spain, ¹¹Rheumatology, Hospital de Basurto, Bilbao, Spain, ¹²Rheumatology, Ophthalmology and rheumatology, Hospital de Ferrol, Ferrol, Ferrol, Spain, ¹³Rheumatology,, Hospital Virgen de la Macarena, Sevilla, Spain, ¹⁴Hospital Dr. Peset., Valencia, Spain
Background/Purpose: In non-infectious no anterior uveitis, adalimumab (ADA) is the only biologic drug that has shown efficacy in phase III randomized, double blind studies,…
Abstract Number: 416 • 2016 ACR/ARHP Annual Meeting
Uveitis Associated to Polyarticular Juvenile Idiopathic Arthritis
Ivan Foeldvari¹, Nicolino Ruperto¹, Daniel J Lovell², Gerd Horneff¹, Hans-Iko Huppertz³, Pierre Quartier⁴, Gabriele Simonini¹, Mareike Bereswill⁵, Jasmina Kalabic⁵, Alberto Martini¹ and Hermine I. Brunner², ¹PRINTO-IRCCS, Genova, Italy, ²PRCSG, Cincinnati, OH, ³PRINTO-IRCCS, Genoa, Italy, ⁴Hôpital Necker-Enfants Malades, Paris, France, ⁵AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany
Background/Purpose: Approximately 10-15% of patients (pts) with juvenile idiopathic arthritis (JIA) experience comorbid uveitis. The objective of this study is to explore events of uveitis and…
Abstract Number: 1337 • 2016 ACR/ARHP Annual Meeting
Effectiveness of Certolizumab Pegol in Patients with Uveitis Refractory to Other Tumor Necrosis Factor Inhibitors. Report of 22 Cases
M. Victoria Hernández¹, Marina Mesquida², Victor Llorens², Maite Sainz de la Maza², Gerard Espinosa³, Ricardo Blanco⁴, Vanesa Calvo⁴, Olga Maiz⁵, Ana Blanco⁶, Juan Ramon De Dios⁷, Pilar Ahijado-Guzman⁸, Enrique Judez⁹, Patricia Tejón¹⁰, M Soledad Peña¹¹, Raimon Sanmarti¹ and Alfredo Adan¹², ¹Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, ²Ophthalmology Department. Hospital Clínic de Barcelona, Barcelona, Spain, ³Autoimmune Diseases Department. Hospital Clínic de Barcelona, Barcelona, Spain, ⁴Rheumatology Department. Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁵Rheumatology Department. Donostia University Hospital, San Sebastian, Spain, ⁶Ophthalmology Department. Donostia University Hospital, Donostia, Spain, ⁷Rheumatology, Hospital Universitario de Araba, Vitoria, Spain, ⁸Avda. Reyes Catolicos, 21, Rheumatology Department. Hospital Infanta Elena, Valdemoro, Madrid, Spain, ⁹Rheumatology Department. Hospital de Albacete, Albacete, Spain, ¹⁰Rheumatology Department. Hospital Universitario General de Castellón, Castellon, Spain, ¹¹Ophtalmology Dpt. Hospital Universitario General de Castellón, Castellon, Spain, ¹²Ophthalmology, Ophthalmology Department. Hospital Clínic de Barcelona, Barcelona, Spain
Background/Purpose: Refractory uveitis may requiere the use of biological therapy, especially tumour necrosis factors inhibitors (TNFi), being the most currently used infliximab and adalimumab. However,…
Abstract Number: 2947 • 2016 ACR/ARHP Annual Meeting
Adalimumab Versus Infliximab in Cystoid Macular Edema of Uveitis Associated to BehçEt Disease. Multicenter Study of 34 Patients
Lucia Cristina Domínguez-Casas¹, Vanesa Calvo-Río¹, Ricardo Blanco², Carlos Fernández-Díaz¹, Paz Rodríguez-Cundín³, Emma Beltran⁴, Marisa Hernández-Garfella⁵, Jose M Herreras⁶, Miguel Cordero-Coma⁷, Marina Mesquida⁸, Alfredo Adan⁹, M. Victoria Hernández¹⁰, David Diaz-Valle¹¹, Ignacio Torre-Salaberri¹², Manuel Díaz-Llopis¹³, Roberto Gallego¹⁴, Olga Maiz-Alonso¹⁵, Santos Insua¹⁶, Félix Francisco¹⁷, Raquel Almodóvar González¹⁸, Oscar Ruiz Moreno¹⁹, Fernando Jiménez-Zorzo²⁰, Javier Manero²¹, Myriam Gandía²², Joan Miquel Nolla²³, Nuria Vegas-Revenga²⁴, Natalia Palmou-Fontana¹ and Miguel Angel Gonzalez-Gay¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ²Rheumatology Department. Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Preventive Medicine, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ⁴Rheumatology, Hospital General Universitario de Valencia, Valencia, Spain, ⁵Ophtamology, Hospital General Universitario de Valencia, Valencia, Spain, ⁶Ophthalmology, Hospital Universitario, IOBA, Valladolid, Spain, ⁷Ophthalmology, Hospital de León, León, Spain, ⁸Ophthalmology, Hospital Clinic. Barcelona. Spain, Barcelona, Spain, ⁹Ophthalmology, Hospital Clinic de Barcelona,, Barcelona, Spain, ¹⁰Rheumatology, Hospital Clinic. Barcelona. Spain, Barcelona, Spain, ¹¹Ophthalmology Department, Hospital Clínico San Carlos, Madrid, Spain, ¹²Rheumatology, Hospital de Basurto, Bilbao, Spain, ¹³Hospital Universitario La Fe, Valencia, Spain, ¹⁴Ophtalmology, Hospital Universitario La Fe, Valencia, Spain, ¹⁵Hospital Universitario Donostia, Donostia, Spain, ¹⁶Rheumatology, Hospital Universitario Santiago de Compostela, La Coruña, Spain, ¹⁷Rheumatology, Hospital Doctor Negrín, Las Palmas de Gran Canaria, Spain, ¹⁸Rheumatology Unit, Hospital Universitario Fundación Alcorcón, Madrid, Spain, ¹⁹Ophthalmology and Rheumatology., Hospital Miguel Servet, Zaragoza, Spain, ²⁰Hospital Miguel Servet, Zaragoza, Spain, ²¹Rheumatology, Hospital Miguel Servet, Zaragoza, Spain, ²²Rheumatology, Hospital Puerta del Mar, Cadiz, Spain, ²³Rheumatology, Department of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ²⁴Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain
Background/Purpose: Cystoid macular edema (CME) is the most serious complication of uveitis and the most common cause of blindness in uveitis. Our aim was…
Abstract Number: 482 • 2016 ACR/ARHP Annual Meeting
Comparison of Nonclinical Pharmacology, Pharmacodynamics and Efficacy Response of the Proposed Adalimumab Biosimilar GP2017 to Originator Adalimumab
Antonio Dasilva¹, Ulrich Kronthaler¹, Hans-Peter Hofmann², Vera Koppenburg¹, Melanie Baron³, Cornelius Fritsch⁴, Otmar Hainzl¹ and Andreas Seidl¹, ¹Sandoz Biopharmaceuticals, Holzkirchen, Germany, ²Pre-clinical, Sandoz Biopharmaceuticals, Holzkirchen, Germany, ³Clinical Development, Sandoz Biopharmaceuticals, Holzkirchen, Germany, ⁴Bioassay Support Global Development, Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Biosimilars are created to be essentially the same as their reference marketed biopharmaceuticals which have lost exclusivity, and they aim to offer more affordable…
Abstract Number: 1408 • 2016 ACR/ARHP Annual Meeting
Impact of Participation in the Adalimumab (Humira) Patient Support Program on Patient Reported Outcomes Among Patients with Rheumatoid Arthritis: Passion Study
Filip van Den Bosch¹, Andrew Östör², Siegfried Wassenberg³, Naijun Chen⁴, Chen Wang⁵, Vishvas Garg⁴ and Jasmina Kalabic⁶, ¹Rheumatology, Ghent University Hospital, Gent, Belgium, ²Addenbrooke's Hospital, Cambridge, United Kingdom, ³Rheumazentrum, Ratingen, Germany, ⁴AbbVie Inc, North Chicago, IL, ⁵AbbVie Inc., North Chicago, IL, ⁶AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany
Background/Purpose: Patient (pt) Support Program (PSP) is offered to pts who are prescribed adalimumab (ADA) for their Rheumatoid arthritis (RA). How participation in a PSP…
Abstract Number: 2983 • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, or Adalimumab in Patients with Active Psoriatic Arthritis and an Inadequate Response to Conventional Synthetic Dmards: A Randomized, Placebo‑Controlled, Phase 3 Trial
Philip J Mease¹, Stephen Hall², Oliver FitzGerald³, Désirée van der Heijde⁴, Joseph F Merola⁵, Francisco Avila-Zapata⁶, Dorata Cieślak⁷, Daniela Graham⁸, Cunshan Wang⁹, Sujatha Menon⁹, Thijs Hendrikx⁸ and Keith Kanik⁹, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Cabrini Health and Monash University, Melbourne, VIC, Australia, ³Department of Rheumatology, St Vincent’s University Hospital and Conway Institute, University College, Dublin, Ireland, ⁴Leiden University Medical Center, Leiden, Netherlands, ⁵Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁶Centro Multidisciplinario para el Desarrollo Especializado de la Investigacion Clinica en Yucatan S.C.P., Yucatán, Mexico, ⁷Poznan University, Poznan, Poland, ⁸Pfizer Inc, Collegeville, PA, ⁹Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor under investigation for treatment of psoriatic arthritis (PsA). This study evaluated tofacitinib efficacy and safety vs placebo…
Abstract Number: 591 • 2016 ACR/ARHP Annual Meeting
Patient-Reported Outcomes for Etanercept Therapy in Adult Patients with Moderate to Severe Rheumatoid Arthritis Who Failed Adalimumab Treatment
Louis Bessette¹, Majed Khraishi², Alan J Kivitz³, Arunan Kaliyaperumal⁴, Rama Grantab⁵, Melanie Poulin-Costello⁵, Maya Isaila⁵ and David Collier⁴, ¹Rhumatology, Centre d’Ostéoporose et de Rhumatologie de Québec (CORQ), Québec, QC, Canada, ²Medical Consultants of West Newfoundland, Western Memorial Hospital, Corner Brook, NF, Canada, ³Altoona Center for Clinical Research, Duncansville, PA, ⁴Amgen Inc., Thousand Oaks, CA, ⁵Amgen Canada Inc., Mississauga, ON, Canada
Background/Purpose: When a tumor necrosis factor inhibitor (TNFi) fails in a patient with moderate to severe rheumatoid arthritis (RA), new American College of Rheumatology (ACR)…
Abstract Number: 1695 • 2016 ACR/ARHP Annual Meeting
Pharmacological Monitoring of Adalimumab and Etanercept-Treated Psoriatic Arthritis Patients in Predicting Future Treatment Response
Meghna Jani¹, Hector Chinoy², Anne Barton² and on behalf of OUTPASS, ¹Centre for Musculoskeletal Research, The University of Manchester, Manchester, United Kingdom, ²Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom
Background/Purpose: Up to 40% of patients with inflammatory arthritis on TNF-α inhibitor (TNFi) treatment fail to respond either due to primary inefficacy or loss of…
Abstract Number: 2987 • 2016 ACR/ARHP Annual Meeting
Comparison of Certolizumab Pegol Versus Adalimumab: 2 Year Efficacy and Safety Results from a Superiority, Investigator-Blind, Head-to-Head Study
Roy Fleischmann¹, Gerd-Rüdiger Burmester², Bernard Combe³, Jeffrey R. Curtis⁴, Stephen Hall⁵, Boulos Haraoui⁶, Ronald van Vollenhoven⁷, Christopher Cioffi⁸, Cécile Ecoffet⁹, Lucian Ionescu⁹, Leon Gervitz¹⁰, Luke Peterson⁸ and Josef Smolen¹¹, ¹University of Texas Southwestern Medical Center at Dallas Metroplex Clinical Research Center, Dallas, TX, ²Charité – University Medicine Berlin, Berlin, Germany, ³Montpellier University Hospital, Montpellier, France, ⁴Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Cabrini Medical Centre, Monash University, Melbourne, Australia, ⁶Department of Medicine, Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada, ⁷Amsterdam Rheumatology and Immunology Center (ARC), Amsterdam, Netherlands, ⁸UCB Pharma, Raleigh, NC, ⁹UCB Pharma, Brussels, Belgium, ¹⁰RA Patient Value Mission, UCB Pharma, Brussels, Belgium, ¹¹Medical University of Vienna and Hietzing Hospital, Vienna, Austria
Background/Purpose: Head-to-head comparisons of biological (b)DMARDs in the treatment of RA should provide rigorous evidence on the comparative efficacy of different treatments. Although there are…
Abstract Number: 602 • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Switching Between Certolizumab Pegol and Adalimumab after Primary Anti-TNF Treatment Failure: 2-Year Results from a Randomized, Investigator-Blind, Superiority Head-to-Head Study
Roy Fleischmann¹, Gerd-Rüdiger Burmester², Bernard Combe³, Jeffrey R. Curtis⁴, Stephen Hall⁵, Boulos Haraoui⁶, Ronald van Vollenhoven⁷, Christopher Cioffi⁸, Cécile Ecoffet⁹, Lucian Ionescu¹⁰, Leon Gervitz¹¹, Luke Peterson⁸ and Josef Smolen¹², ¹University of Texas Southwestern Medical Center at Dallas Metroplex Clinical Research Center, Dallas, TX, ²Charité – University Medicine Berlin, Berlin, Germany, ³Montpellier University Hospital, Montpellier, France, ⁴The University of Alabama at Birmingham, Birmingham, AL, ⁵Cabrini Medical Centre, Monash University, Melbourne, Australia, ⁶Department of Medicine, Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada, ⁷Amsterdam Rheumatology and Immunology Center (ARC), Amsterdam, Netherlands, ⁸UCB Pharma, Raleigh, NC, ⁹UCB Pharma, Brussels, Belgium, ¹⁰Allée De La Recherche 60, UCB Pharma, Brussels, Belgium, ¹¹RA Patient Value Mission, UCB Pharma, Brussels, Belgium, ¹²Medical University of Vienna and Hietzing Hospital, Vienna, Austria
Background/Purpose: EULAR, ACR and treat-to-target guidelines recommend switching treatment in inadequate responders (IRs) to alternative therapy by Week (Wk) 12.1-3 Although any biological (b)DMARD can…
Abstract Number: 1696 • 2016 ACR/ARHP Annual Meeting
Minimal Disease Activity Is a Stable Measure of Therapeutic Response in Psoriatic Arthritis Patients Receiving Treatment with Adalimumab
Frank Behrens¹, Michaela Koehm², Eva Christina Schwaneck³, Marc Schmalzing⁴, Holger Gnann⁵, Gerd Greger⁶, Hans-Peter Tony⁷ and Harald Burkhardt¹, ¹Division of Rheumatology and Fraunhofer IME-Project-Group Translational Medicine and Pharmacology, Goethe University, Frankfurt, Germany, ²Division of Rheumatology and Fraunhofer IME-Project-Group Translational Medicine and Pharmacology, Goethe University, Frankfurt/Main, Germany, ³Rheumatology/Immunology, Medical Clinic II, University Clinic Wuerzburg, Wuerzburg, Germany, ⁴Rheumatology/Clinical Immunology, Medical Clinic II, University Clinic Wuerzburg, Würzburg, Germany, ⁵Abteilung Biostatistik, GKM Gesellschaft für Therapieforschung mbH, München, Germany, ⁶AbbVie Deutschland GmbH & Co.KG, Wiesbaden, Germany, ⁷Rheumatology/Immunology, Medical Clinic II, University Clinic Wuerzburg, Würzburg, Germany
Background/Purpose: Minimal disease activity (MDA) is an important goal for patients with rheumatologic disorders, including psoriatic arthritis (PsA). The assessment of MDA could potentially help…

« Previous Page
1
…
6
7
8
9
10
…
17
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].